Cargando…
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma worldwide, representing 30–40% of non-Hodgkin lymphomas, and is clinically aggressive. Although more than half of patients with DLBCL are cured by using standard first-line immunochemotherapy, the remaining patients are refrac...
Autores principales: | Miao, Yi, Medeiros, L. Jeffrey, Xu-Monette, Zijun Y., Li, Jianyong, Young, Ken H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406015/ https://www.ncbi.nlm.nih.gov/pubmed/30881917 http://dx.doi.org/10.3389/fonc.2019.00107 |
Ejemplares similares
-
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Zhang, Jun, et al.
Publicado: (2018) -
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
por: Lu, Tingxun, et al.
Publicado: (2023) -
Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma
por: Yu, Tiantian, et al.
Publicado: (2023) -
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
por: Chen, Jiayu, et al.
Publicado: (2015) -
Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)